Drug Detail:Femring (Estradiol vaginal (systemic) [ es-tra-dye-ole-va-jin-ul ])
Generic Name: ESTRADIOL ACETATE 0.05mg in 1d
Dosage Form: vaginal ring
Drug Class: Estrogens
Drug Detail:Femring (Estradiol vaginal (systemic) [ es-tra-dye-ole-va-jin-ul ])
Generic Name: ESTRADIOL ACETATE 0.05mg in 1d
Dosage Form: vaginal ring
Drug Class: Estrogens
Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer.
A woman without a uterus does not need a progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin [see Warnings and Precautions (5.2, 5.14)].
Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
Start therapy with 0.05 mg/day. Dosage adjustment should be guided by the clinical response.
Therapy should be started at the lowest effective dose and the shortest duration consistent with treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals.
Start therapy with 0.05 mg/day. Dosage adjustment should be guided by the clinical response.
Therapy should be started at the lowest effective dose and the shortest duration consistent with treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals.